Financial Tearsheet

Company Overview

ENDRA Life Sciences' mission is to bring new capabilities to ultrasound and broaden access to better healthcare.

ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound (TAEUS™) system to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT & MRI -- at a fraction of the cost, and at the point-of-care.

ENDRA's first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease, which affects over 1 billion people globally.

Recent Financial News

IR Contacts

LHA Investor Relations

Kim Sutton Golodetz
212-838-3777
kgolodetz@lhai.com
https://www.lhai.com

Stock Performance

Today's Open 2.55
Volume 2.65 million
Day Range 2.46 - 2.69
52 Week Range 0.60 - 2.99
Bid/Ask 2.61 / 2.62
Bid/Ask Size 1,300 X 2,700
Previous Close 2.50
Market Cap 88.81 million
Shares Outstanding 33.64 million
Dividend/Yield 0.00 / 0.00%
EPS (TTM) -1.830400
P/E Ratio (TTM) N/A

Recent XBRL Filings

Filing Date Form Type Description View
Nov 16, 2020 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
Aug 14, 2020 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
May 14, 2020 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
Mar 26, 2020 10-K Annual report htmlhtml   pdfpdf   xbrlxbrl  
Nov 13, 2019 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  

Management Team

Francois Michelon, Chief Executive Officer and Chairman

Michael Thornton, Chief Technology Officer

David Wells, Chief Financial Officer

Amy Sitzler, Vice President of Engineering and Programs

Steve Freeman, Human Resources Leader

Renaud Maloberti, Chief Commercial Officer

Board of Directors

Francois Michelon, Chairman of the Board

Louis Basenese, Director

Anthony DiGiandomenico, Director

Michael Harsh, Director

Alexander Tokman, Director